India, Sept. 17 -- Capricor Therapeutics (CAPR) will present new data from its Phase 3 HOPE-3 study and open-label extension (OLE) of deramiocel at the 2026 World Muscle Society Congress, taking place between September 29 and October 3, 2026, in Hiroshima, Japan.
The presentations will provide updated findings on skeletal muscle and cardiac outcomes through 24 months in patients with Duchenne muscular dystrophy (DMD), a severe X-linked genetic disorder marked by progressive degeneration of skeletal, respiratory and cardiac muscles.
The upcoming data build on the 12-month HOPE-3 results and the 24-month OLE data submitted by Capricor to the FDA as part of a Biologics License Application (BLA) amendment in August. The FDA accepted the amend...